{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:30:28Z","timestamp":1775226628480,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"10016","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100018465","name":"Regado Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/s0140-6736(15)00515-2","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T08:11:23Z","timestamp":1446711083000},"page":"349-356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"title":["Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial"],"prefix":"10.1016","volume":"387","clinical-trial-number":[{"clinical-trial-number":"nct01848106","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"A Michael","family":"Lincoff","sequence":"first","affiliation":[]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[]},{"given":"Thomas J","family":"Povsic","sequence":"additional","affiliation":[]},{"given":"Steven L","family":"Zelenkofske","sequence":"additional","affiliation":[]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[]},{"given":"Paul W","family":"Armstrong","sequence":"additional","affiliation":[]},{"given":"P Gabriel","family":"Steg","sequence":"additional","affiliation":[]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[]},{"given":"Mauricio G","family":"Cohen","sequence":"additional","affiliation":[]},{"given":"Christopher","family":"Buller","sequence":"additional","affiliation":[]},{"given":"Peep","family":"Laanmets","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[]},{"given":"Toomas","family":"Marandi","sequence":"additional","affiliation":[]},{"given":"Viliam","family":"Fridrich","sequence":"additional","affiliation":[]},{"given":"Warren J","family":"Cantor","sequence":"additional","affiliation":[]},{"given":"Bela","family":"Merkely","sequence":"additional","affiliation":[]},{"given":"Jose","family":"Lopez-Sendon","sequence":"additional","affiliation":[]},{"given":"Jan H","family":"Cornel","sequence":"additional","affiliation":[]},{"given":"Jaroslaw D","family":"Kasprzak","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Aschermann","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Guetta","sequence":"additional","affiliation":[]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[]},{"given":"Peter R","family":"Sinnaeve","sequence":"additional","affiliation":[]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[]},{"given":"Rod","family":"Stables","sequence":"additional","affiliation":[]},{"given":"Mary Ann","family":"Sellers","sequence":"additional","affiliation":[]},{"given":"Marilyn","family":"Borgman","sequence":"additional","affiliation":[]},{"given":"Lauren","family":"Glenn","sequence":"additional","affiliation":[]},{"given":"Arnold I","family":"Levinson","sequence":"additional","affiliation":[]},{"given":"Renato D","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Vic","family":"Hasselblad","sequence":"additional","affiliation":[]},{"given":"Richard C","family":"Becker","sequence":"additional","affiliation":[]},{"given":"John H","family":"Alexander","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(15)00515-2_bib1","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jacc.2010.10.030","article-title":"Efficacy and safety of glycoprotein IIb\/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the eral of stents and thienopyridines","volume":"57","author":"Winchester","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/S0140-6736(15)00515-2_bib2","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(15)00515-2_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ahj.2007.10.014","article-title":"Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes","volume":"155","author":"Rao","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/S0140-6736(15)00515-2_bib4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","article-title":"Impact of bleeding on mortality after percutaneous coronary intervention","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/S0140-6736(15)00515-2_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"Cavender","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(15)00515-2_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature00963","article-title":"RNA aptamers as reversible antagonists of coagulation factor IXa","volume":"419","author":"Rusconi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(15)00515-2_bib7","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1161\/CIRCULATIONAHA.107.745687","article-title":"Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease","volume":"117","author":"Chan","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(15)00515-2_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1538-7836.2008.02932.x","article-title":"A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor","volume":"6","author":"Chan","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/S0140-6736(15)00515-2_bib9","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","article-title":"First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity","volume":"114","author":"Dyke","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(15)00515-2_bib10","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1093\/eurheartj\/ehr179","article-title":"Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy","volume":"32","author":"Povsic","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(15)00515-2_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ahj.2010.10.022","volume":"161","author":"Povsic","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/S0140-6736(15)00515-2_bib12","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial","volume":"34","author":"Povsic","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/S0140-6736(15)00515-2_bib13","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(15)00515-2_bib14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(15)00515-2_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejps.2012.10.014","article-title":"Therapeutic RNA aptamers in clinical trials","volume":"48","author":"Sundaram","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/S0140-6736(15)00515-2_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/S0140-6736(15)00515-2_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev.med.56.062904.144915","article-title":"Aptamers: an emerging class of therapeutics","volume":"56","author":"Nimjee","year":"2005","journal-title":"Annu Rev Med"},{"key":"10.1016\/S0140-6736(15)00515-2_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.ATV.0000259363.91070.f1","article-title":"Factor IXa inhibitors as novel anticoagulants","volume":"27","author":"Howard","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/S0140-6736(15)00515-2_bib19","first-page":"578","article-title":"Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation","volume":"80","author":"Kjalke","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/S0140-6736(15)00515-2_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00001721-199606000-00005","article-title":"Transmission of a procoagulant signal from tissue factor-bearing cells to platelets","volume":"7","author":"Monroe","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/S0140-6736(15)00515-2_bib21","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1172\/JCI115495","article-title":"Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model","volume":"88","author":"Benedict","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/S0140-6736(15)00515-2_bib22","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1161\/01.ATV.19.10.2554","article-title":"Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats","volume":"19","author":"Feuertein","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/S0140-6736(15)00515-2_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/hq0302.105375","article-title":"A human antibody that inhibits factor IX\/IXa function potently inhibit arterial thrombosis without increasing bleeding","volume":"22","author":"Refino","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/S0140-6736(15)00515-2_bib24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCULATIONAHA.109.927756","article-title":"First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention","volume":"122","author":"Cohen","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/S0140-6736(15)00515-2_bib25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/s120100612","article-title":"Aptamers and their biological applications","volume":"12","author":"Song","year":"2012","journal-title":"Sensors"},{"key":"10.1016\/S0140-6736(15)00515-2_bib26","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.2174\/092986711797189600","article-title":"Nucleic acid aptamers: clinical applications and promising new horizons","volume":"18","author":"Ni","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/S0140-6736(15)00515-2_bib27","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/S0140-6736(15)00515-2_bib28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinectics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0140-6736(15)00515-2_bib29","first-page":"258","article-title":"Uricase and other novel agents for the management of patients with treatment-failure gout","volume":"9","author":"Sundy","year":"2007","journal-title":"Curr Rheumatol"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673615005152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673615005152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T09:54:04Z","timestamp":1655373244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673615005152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":29,"journal-issue":{"issue":"10016","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0140673615005152"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(15)00515-2","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(15)00515-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(15)00727-8","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}